Five specialty pharmaceutical trends to watch Posted on October 13, 2016 by henrykotula • Posted in Uncategorized • Tagged FDA, Biosimilars, Pharmaceutical Industry, Pharmaceutical Specialty Trends, Noninterchangeable Biosimilar, Filgrastim, Pegfilgrastim, SB2 infliximab, Epoetin alfa, CHSâ€1701, Cancer Drug Development, Orphan Drug Development • Leave a comment http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/five-specialty-pharmaceutical-trends-watch?cfcache=true&GUID=A13E56ED-9529-4BD1-98E9-318F5373C18F&rememberme=1&ts=13102016 Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on LinkedIn (Opens in new window) LinkedIn Like Loading...
HENRY KOTULA 